Explore

Trendline Trendline
IGC Pharma Advances Alzheimer's Trial, Reports Financial Results

IGC Pharma Advances Alzheimer's Trial, Reports Financial Results

IGC Pharma Advances Alzheimer's Trial, Reports Financial Results
Trendline Trendline
Oligomerix Completes Phase 1a Study of Alzheimer's Drug OLX-07010, Showing Promising Safety Profile

Oligomerix Completes Phase 1a Study of Alzheimer's Drug OLX-07010, Showing Promising Safety Profile

Oligomerix Completes Phase 1a Study of Alzheimer's Drug OLX-07010, Showing Promising Safety Profile
Trendline Trendline
Sanofi's Experimental Therapy for AATD Shows Promise in Phase 2 Trial

Sanofi's Experimental Therapy for AATD Shows Promise in Phase 2 Trial

Sanofi's Experimental Therapy for AATD Shows Promise in Phase 2 Trial
Trendline Trendline
IntraBio Begins Phase III Trial for CACNA1A-Related Disorders

IntraBio Begins Phase III Trial for CACNA1A-Related Disorders

IntraBio Begins Phase III Trial for CACNA1A-Related Disorders
Trendline Trendline
Lantern Pharma's HARMONIC Trial Receives FDA Support for Protocol Amendments in NSCLC Treatment

Lantern Pharma's HARMONIC Trial Receives FDA Support for Protocol Amendments in NSCLC Treatment

Lantern Pharma's HARMONIC Trial Receives FDA Support for Protocol Amendments in NSCLC Treatment
Trendline Trendline
Turn Therapeutics to Present GX-03 at Jefferies Global Healthcare Conference

Turn Therapeutics to Present GX-03 at Jefferies Global Healthcare Conference

Turn Therapeutics to Present GX-03 at Jefferies Global Healthcare Conference
Trendline Trendline
ImmunityBio's ANKTIVA Plus BCG Receives FDA Review for Expanded Bladder Cancer Treatment

ImmunityBio's ANKTIVA Plus BCG Receives FDA Review for Expanded Bladder Cancer Treatment

ImmunityBio's ANKTIVA Plus BCG Receives FDA Review for Expanded Bladder Cancer Treatment
Trendline Trendline
Oligomerix Completes Phase 1a Study of Alzheimer's Drug OLX-07010, Showing Promise for Future Trials

Oligomerix Completes Phase 1a Study of Alzheimer's Drug OLX-07010, Showing Promise for Future Trials

Oligomerix Completes Phase 1a Study of Alzheimer's Drug OLX-07010, Showing Promise for Future Trials
Trendline Trendline
Sumitomo Pharma America Presents Promising Vibegron Data for Older Men with Overactive Bladder

Sumitomo Pharma America Presents Promising Vibegron Data for Older Men with Overactive Bladder

Sumitomo Pharma America Presents Promising Vibegron Data for Older Men with Overactive Bladder
Trendline Trendline
AI's Role in Transforming Biotechnology: Enhancing Drug Discovery and Personalized Medicine

AI's Role in Transforming Biotechnology: Enhancing Drug Discovery and Personalized Medicine

AI's Role in Transforming Biotechnology: Enhancing Drug Discovery and Personalized Medicine
Trendline Trendline
Turn Therapeutics Appoints Former FDA Commissioner Dr. Stephen M. Hahn to Lead Clinical and Regulatory Strategy

Turn Therapeutics Appoints Former FDA Commissioner Dr. Stephen M. Hahn to Lead Clinical and Regulatory Strategy

Turn Therapeutics Appoints Former FDA Commissioner Dr. Stephen M. Hahn to Lead Clinical and Regulatory Strategy
Trendline Trendline
ImmunityBio Secures Exclusive U.S. Rights to Tokyo Strain of BCG to Address Bladder Cancer Treatment Shortage

ImmunityBio Secures Exclusive U.S. Rights to Tokyo Strain of BCG to Address Bladder Cancer Treatment Shortage

ImmunityBio Secures Exclusive U.S. Rights to Tokyo Strain of BCG to Address Bladder Cancer Treatment Shortage